Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial
Randomized controlled trial published in Journal of cardiovascular translational research (2014)
Abstract
Early invasive management and the use of combined antithrombotic therapies have decreased the risk of recurrent ischaemia in patients with acute coronary syndrome (ACS) but have also increased the bleeding risk. Transradial intervention (TRI) and bivalirudin infusion compared to transfemoral intervention (TFI) or unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) decrease bleeding complications in patients with ACS. To what extent, a bleeding preventive strategy incorporating at least one of these two treatment options translates into improved outcomes is a matter of debate. The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX study is a large-scale, multicenter, prospective, open-label trial, conducted at approximately 100 sites in Europe aiming to primarily assess whether TRI and bivalirudin infusion, as compared to TFI and UFH plus provisional GPI, decrease the 30-day incidence of death, myocardial infarction or stroke across the whole spectrum of ACS patients.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Early invasive management and the use of combined antithrombotic therapies have decreased the risk of recurrent ischaemia in patients with acute coronary syndrome (ACS) but have also increased the bleeding risk.
Por qué esto importa para la hirudoterapia
Este artículo describe la base científica y el diseño del ensayo MATRIX, un ensayo prospectivo, abierto, multicéntrico a gran escala realizado en aproximadamente 100 sitios en Europa, que evalúa la intervención transradial e infusión de bivalirudina versus la intervención transfemoral con heparina no fraccionada más inhibidores provisionales de la glucoproteína IIb/IIIa para el síndrome coronario agudo. El ensayo busca evaluar si este enfoque disminuye la incidencia a 30 días de muerte, infarto de miocardio o accidente cerebrovascular a lo largo del espectro de pacientes con síndrome coronario agudo. El resumen no menciona sanguijuelas, hirudoterapia ni ninguna relación entre la bivalirudina y los compuestos derivados de sanguijuelas. En consecuencia, no puede establecerse una relevancia defendible para la American Society of Hirudotherapy a partir del resumen solo.
Citación
Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial
Valgimigli M et al. · Journal of cardiovascular translational research, 2014
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026